Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $4.42 Million - $5.9 Million
-33,400 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $2.03 Million - $5.41 Million
33,400 New
33,400 $5.41 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $825M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.